SSRIs
PreclinicalSmall molecule
Eli LillySSRIs is one of 140 small molecule programs targeting Sexual Dysfunction. It is currently in Preclinical.
4
Indications
13
Total Trials
5
Active Trials
139
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Fetzima
AbbViePhase 3
ALKS 37
AAlkermes, Inc.
Phase 3
Desvenlafaxine SR
PfizerPhase 3
Vraylar
AbbViePhase 3
CYB003
CCybin IRL Limited
Phase 3
NBI-1065845
Neurocrine BiosciencesPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Major Depressive Disorder6 trials
Intradermal Needle Therapy for Major Depressive Disorder
Unknown status·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·N/A·NCT05352113·120 enrolled
Show 3 more trials
Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive Disorder
Unknown status·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·N/A·NCT05353543·120 enrolled
Obsessive-Compulsive Disorder2 trials
Post-Traumatic Stress Disorder1 trial
Sexual Dysfunction1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSRIs. EMBL-EBI & Wellcome Sanger Institute.
- [4]